Moderna stands to earn $300M for quick vaccine approval, up to $6.6B for extra doses: filing

Moderna's coronavirus vaccine deal with the U.S., announced last week with a $1.525 billion price tag, would be worth far more if all options are exercised—and if the mRNA biotech meets an aggressive timeline for the shot's arrival.